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It is widely held that changes in the distribution of mutant mtDNAs underlie the progressive nature of mtDNA
diseases, but there are few data documenting such changes. We compared the levels of 3243 ArG mutant mtDNA
in blood at birth from Guthrie cards and at the time of diagnosis in a blood DNA sample from patients with
mitochondrial encephalopathy, lactic acidosis, and strokelike episodes (MELAS) syndrome. Paired blood DNA
samples separated by 9–19 years were obtained from six patients with MELAS. Quantification of mutant load, by
means of a solid-phase minisequencing technique, demonstrated a decline (range 12%–29%) in the proportion of
mutant mtDNA in all cases ( , paired t-test). These results suggest that mutant mtDNA is slowly selectedPp .0015
from rapidly dividing blood cells in MELAS.
Mitochondrial encephalopathy, lactic acidosis, and
strokelike episodes (MELAS [MIM 540000]) is a neu-
rological disease of either child or adult onset. Approx-
imately 80% of patients with MELAS (Goto et al. 1990;
Kobayashi et al. 1990), as well as ∼1% of patients with
non–insulin-dependent diabetes mellitus (van den
Ouweland 1994), carry the nucleotide (nt) 3243 ArG
point mutation in the tRNA leucineUUR gene of mito-
chondrial DNA (mtDNA). The population frequency of
the mutation is ∼1:15,000, making it one of the most
common neurogenetic diseases (Majamaa et al. 1998).
Noninvasive diagnosis of MELAS by means of blood
DNA has become a routine procedure (Hammans et al.
1991). However, 3243 ArG mutant mtDNA levels have
been noted to be consistently lower in blood than in
skeletal muscle (Ciafaloni et al. 1992), which may some-
times cause a false negative finding in diagnosis of ME-
LAS. Furthermore, cross-sectional data demonstrated
that the difference between levels in blood and skeletal
muscle is proportional to age, which might be explained
by declining mutant mtDNA levels in blood as a result
of preferential selection of cells containing high levels of
wild-type mtDNA (Poulton and Morten 1993). To test
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this hypothesis, we retrieved dried neonatal blood spots
from six patients known to have 3243 ArG MELAS
and compared longitudinally the level of the mutant
mtDNA in blood at birth with that at the time of di-
agnosis, the two samples being separated by 9–19 years.
After informed patient consent, five Guthrie-card
specimens with dried neonatal blood spots from unre-
lated patients diagnosed with MELAS syndrome were
obtained from neonatal screening centers in the United
Kingdom. A genomic DNA sample, extracted from leu-
kocytes of each patient by routine methods at the time
of diagnosis of MELAS, accompanied each Guthrie card.
An additional patient, who has had two DNA samples
taken 12 years apart, was included. For Guthrie-card
specimens, a 3-mm diameter punch was cut, with a ster-
ile scalpel and forceps from each card, directly into a
0.5-ml PCR tube. The samples were incubated twice in
0.5 ml ddH2O for 30 min at room temperature and
were vacuum dried prior to PCR (Makowski et al.
1995). For controls, we included a Guthrie spot from a
patient with no MELAS mutation and a piece of Guthrie
card outside the blood spot. The PCR mix was added
directly onto the card sample or, in the case of the DNA
samples, to 50 ng of genomic DNA. The PCR and sub-
sequent mutation analysis of the 62-bp PCR product by
the solid-phase minisequencing technique (Syva¨nen et al.
1990) were carried out as described elsewhere (Suoma-
lainen et al. 1993). To obtain a mixture of lymphocytes
and monocytes, mutant load in individual blood cell
series was determined for patient 6 by separating the
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Figure 1 Mutant load in blood, declining over the time period
between the two samples.
Table 1
Quantification of 3243 ArG Mutant mtDNA in Guthrie
Card Samples at Birth and Blood Samples at the Time
of Diagnosis from Patients with MELAS: Results of a
Solid-Phase Minisequencing Assay
Subject
Age
(years)
Cpm C
(mutant)a
Cpm T
(wild type)
Mutant
mtDNA
(%)b
1 Birth 23603 13696 58
1 15 34275 33355 45
2 Birth 26183 8973 70
2 15 29267 33502 41
3 Birth 42530 9270 79
3 11 36124 18389 61
4 Birth 44029 10978 76
4 9 34320 15303 64
5 Birth 12894 42136 20
5 19 6135 59298 8
6 23 28526 41239 36
6 35 16518 53456 20
Controlc 347 408
Controld 48 52
a When the MELAS ArG mutation at nt 3243 is pre-
sent, two Cs are incorporated in the assay.
b The specific activities of the 3H-labeled nucleotides
were for dCTP 64 Ci/mmol and for dTTP 102 Ci/mmol.
The percentage of mutant mtDNA was calculated accord-
ing to the following formula: Cpm C/[cpm c
, in(cpm t# 1.25)]# 100%p% of mutant mtDNA
which the coefficient 1.25 corrects for incorporation of
two Cs in the case of the mutation, as well as the difference
between the specific activities of the two dNTPs.
c Card with no blood.
d No DNA.
buffy coat by use of a percoll gradient. Monocytes were
separated by adherence to plastic tissue culture wells for
60 min at 37C (Romani 1996).
We observed progressive decline of mutant mtDNA
in all patients with MELAS (table 1, fig. 1). The observed
decrease ranged from 12% to 29% and was statistically
significant ( , paired t-test). The mean ratePp .0015
of decline per year was 1.4% (range 0.6–1.9). In patient
6, the mutant load was not significantly different be-
tween blood cell types, being 24%, 20%, and 20% in
monocytes, lymphocytes, and total blood leukocytes, re-
spectively. Thus, even extreme alterations in the blood
components could not underlie a fall in level of 3243
ArG mutant mtDNA of the magnitude that we docu-
mented.
The 3243 ArG mutation causes a defect in mito-
chondrial translation leading to impaired oxidative
phosphorylation (OXPHOS), with deficient activity of
respiratory chain complexes I and/or IV (Koga et al.
1988; Ciafaloni et al. 1992). Therefore, a possible mech-
anism of clearance of mutant mtDNA from rapidly di-
viding blood cells is by natural selection along Darwin-
ian principles: cells with a high mutant mtDNA load
have impaired OXPHOS capacity and may divide less
frequently than cells with low mutant mtDNA content.
Our long-term results show that the selection seems to
be a general feature of mtDNA carrying the 3243 ArG
mutation in blood, having a constant rate of decline.
Our results agree well with another study (t’ Hart et al.
1996), which observed a decline in the mutant 3243
ArG mtDNA in paired blood samples taken 1.5–6 years
apart from diabetes pedigrees. A recent study reported
no evidence of loss of A3243G mutant mtDNA from
hair follicles, which are rapidly dividing but do not have
a high energy requirement (Sue et al. 1998). These data
contrast with those on other tissues and cultured cells,
in which mutant mtDNA may accumulate (Larsson et
al. 1990, 1992; Weber et al. 1997). In a study of Leber’s
hereditary optic neuropathy, the heteroplasmic mutant
mtDNA amount remained constant for 13.5 years
(Ghosh et al. 1996). The authors concluded that no
measurable selection pressures operated for or against
the 3460 mutant mtDNA in this short time period and
that random genetic drift was occurring. These data sug-
gest that, in rapidly dividing tissues, mtDNA drifts ran-
domly if the mutant mtDNA does not cause a severe
respiratory defect, whereas in the case of 3243 ArG
mutant mtDNA with a generalized severe effect on res-
piration, slow selection for the wild type is present. This
selection is not likely to be caused by active selection at
the mtDNA level but merely by the fitness of the cell to
divide. Our data show that DNA diagnosis of MELAS
in elderly individuals should be based on analysis of
tissues in which the levels of mutant mtDNA are likely
to be high, such as muscle or probably hair follicles. In
this and in many other mtDNA diseases, there is a dan-
ger of false-negative results when DNA from leukocytes
is used.
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